Xbrane Biopharma releases interim report for January – March 2021

Xbrane Biopharma AB’s (publ.) (”Xbrane”) interim report for January – March 2021 is now available on the Company’s website, www.xbrane.com.

Financial summary first quarter 2021

• Revenue amounted to SEK 0m (0).
• Other operating income amounted to SEK 4.1m (4.9).
• EBITDA was SEK -49.0m (-50.0*).
• R&D expenses amounted to SEK 46.0m (-47.5*) representing 83 percent (84*) of total operating expenses.
• The loss for the period was SEK 51.3m (-51.8*).
• Earnings per share was SEK -2.31 (-3.36*).
• Cash and cash equivalents at the end of the period amounted to SEK 239.2m (84.5).

*This period has been recalculated due to restatement, see Appendix 1 in the interim report for the effects.

Significant events during the first quarter 2021

• In early January 2021, Xbrane renegotiated an existing intellectual property license agreement with Vaxiion Therapeutics.
• Xbrane signed a non-binding letter of intent with New FaDem in February 2021, regarding the divestment of the subsidiary Primm Pharma.
• Anette Lindqvist took over as Chief Financial Officer & Head of Investor Relations in early January 2021 and Erik Domines took over as General Counsel in March 2021.
• Xbrane established a new development laboratory for biosimilars at Campus Solna outside Stockholm in March 2021.

Significant events after the period

• There have been no significant events after the end of the quarter.

Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on May the 6th, 2021, at 10.00 a.m. CET. See below link and call-in details to the presentation below.

Web link:
https://edge.media-server.com/mmc/p/eq2kbejf

Standard international: +44 (0) 2071 928 338
UK (Local): +44 (0) 844 481 97 52
UK (Tollfree): 800 279 66 19

Sweden (Local): +46 (0) 856 618 467
Sweden (TollFree): 020 012 51 60

US (Local): +1 646 741 31 67
US (TollFree): +1 877 870 91 35

Confirmation Code: 516 34 48